(RTTNews) - Pfizer Inc. (PFE) reported Thursday that its ongoing Phase 2 study of investigational Tilrekimig met its primary endpoint in adults with moderate to severe atopic dermatitis.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.